FDA Biosimilars Program Gets Seed Money In Administration's FY '11 Budget
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency again requests generic user fee program, seeking to add $38 million in industry funds to $88.5 million in federal money for reviewing generics.